anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Despite advances in neonatal care, the incidence of Bronchopulmonary Dysplasia (BPD) remains high among preterm infants. Human induced pluripotent stem cells (hiPSCs) have shown promise in repairing injury in animal BPD models. Evidence suggests they exert their effects via paracrine mechanisms. We aim herein to assess the effectiveness of extracellular vesicles (EVs) derived from hiPSCs and their alveolar progenies (diPSCs) in attenuating hyperoxic injury in a preterm lung explant model.
METHODS: Murine lung lobes were harvested on embryonic day 17.5 and maintained in air-liquid interface. Following exposure to 95% O2 for 24 h, media was supplemented with 5 × 106 particles/mL of EVs isolated from hiPSCs or diPSCs by size-exclusion chromatography. On day 3, explants were assessed using Hematoxylin-Eosin staining with mean linear intercept (MLI) measurements, immunohistochemistry, VEGFa and antioxidant gene expression. Statistical analysis was conducted using one-way ANOVA and Multiple Comparison Test. EV proteomic profiling was performed, and annotations focused on alveolarization and angiogenesis signaling pathways, as well as anti-inflammatory, anti-oxidant, and regenerative pathways.
RESULTS: Exposure of fetal lung explants to hyperoxia induced airspace enlargement, increased MLI, upregulation of anti-oxidants Prdx5 and Nfe2l2 with decreased VEGFa expression. Treatment with hiPSC-EVs improved parenchymal histologic changes. No overt changes in vasculature structure were observed on immunohistochemistry in our in vitro model. However, VEGFa and anti-oxidant genes were upregulated with diPSC-EVs, suggesting a pro-angiogenic and cytoprotective potential. EV proteomic analysis provided new insights in regard to potential pathways influencing lung regeneration.
CONCLUSION: This proof-of-concept in vitro study reveals a potential role for hiPSC- and diPSC-EVs in attenuating lung changes associated with prematurity and oxygen exposure. Our findings pave the way for a novel cell free approach to prevent and/or treat BPD, and ultimately reduce the global burden of the disease.
OF THE INVENTION A system for preparing a pharmaceutical compound comprises: a scale having a platen configured for placement of an object thereon; a supporting arm comprising a first end coupled to a portion of the scale and a second end extending to a position above the platen of the scale; and an enclosure housing extending from the second end of the supporting arm and configured to house at least one input device. The enclosure housing has a curved front profile to minimize flow disturbance when the system is positioned within a flow hood. +16 16 . 1 - - z Y SCALE WEIGHING SURFACE a b b FIG. 15 FIG. 16
The invention relates to the method for treating the chronic viral hepatitis C and comprises the use of preparations originating from embryofetal material and containing the therapeutically effective amount of the stem cells. The stem cells isolated from human fetus (6-13 weeks of gestation) are prepared as the cryopreserved cell suspensions. Two preparations are used, namely, the suspensions of stem cells from fetal liver and progenitor cells for the connective tissue isolated from the fetal soft tissues. The stem cells from fetal liver are injected intravenously in a volume of at least 0.1 mL at a concentration of at least 2.89 × 106 nucleated cells in 1 ml. The stem cells from the fetal soft tissues are injected subcutaneously in a volume of at least 0.5 mL at a concentration of at least 1.52 × 106 cells in 1 ml. The injection of the suspensions of stem cells accompanies the standard medicamentous therapy. The injection of stem cells from fetal liver is preceded by premedication.
PURPOSE: To provide an alcoholic irritating odor masking agent capable of supporting the irritating odor by alcohol in a cosmetic, a drink, a food and a perfume containing alcohol, by consisting the masking agent of an ester represent by a general formula such as methyl acetate, ethyl acetate or isoamyl acetate. CONSTITUTION: This alcoholic irritating odor masking agent consists of an ester represented by a general formula such as methyl acetate, ethyl acetate or isoamyl acetate (R1 and R2 each represents a short chain alkyl group allowed to be independently branched). The above alcohol is ethanol. Either one kind selected from these esters or a mixture of >=2 kinds can be used as the masking agent. The concentration of the masking agent capable of effectively exhibiting the action is 0.1-10wt.%, more preferably 0.5-5wt.% based on the alcohol in a case via the sense of smell such as in perfumes, etc. The action is remarkable and physical properties of lower alcohols such as solubility are not damaged. In a case via both senses of smell and taste such as in drinks or foods, a concentration of 0.01-2000ppm is preferable.
The invention discloses a fresh pseudo-ginseng activity extractive, a preparation method of the fresh pseudo-ginseng activity extractive, a preparation and an application. The fresh pseudo-ginseng activity extractive is prepared by taking fresh pseudo-ginseng as raw material, and performing pre-treatment, extraction, separation, and post-treatment techniques; the fresh pseudo-ginseng activity extractive is yellow green, wherein the content of the volatile oil is more than 0.1%.. The preparation method comprises pre-treatment, extraction, separation, and post-treatment. The preparation is pure powder of fresh pseudo-ginseng activity extractive, or prepared to be powder, tablet, granule, capsule and pill by adding pharmaceutically acceptable auxiliary materials. The application is the application of fresh pseudo-ginseng activity extractive in preparing drugs, foods and health-care foods for improving angiocarpy and coronary microcirculation. The invention uses the fresh pseudo-ginseng (including preserved fresh pseudo-ginseng) as raw material, and gathers complete active original essence of the concentrated fresh pseudo-ginseng, and realizes the convenience of storage and carrying of the fresh pseudo-ginseng; the fresh pseudo-ginseng can be used efficiently.
Subjects will have headphones placed on 1 minute prior to procedural sedation. No music will be played. The headphones will be removed when the subject is fully awake.
The PCDM intervention will include evaluation of CHF care by the collaborative care team, with diagnostic and therapeutic treatment recommendations based on current ACC/AHA national clinical practice guidelines, daily telemonitoring and patient self-care support utilizing the VA telemonitoring system, and screening and treatment for comorbid depression. The Collaborative Care (CC) team at each site will consist of a primary care provider, cardiologist, and psychiatrist, who are local opinion leaders, as well as a nurse site coordinator and pharmacist. For a given intervention patient, there will be an initial assessment of care by the CC team following the enrollment visit. Each intervention patient will be re-reviewed by the CC team a minimum of 2 additional times (at 6-weeks and 6 months). In addition, patients will have daily telemonitoring, and their care will be reviewed by the CC team if the telemonitoring data suggests clinical deterioration.
Background The development of existing follow-up strategies is mainly based on experts' consensus and researches on recurrence patterns due to the lack of direct evidence and unified standards. On the one hand, it is unreasonable to carry out the same postsurgical surveillance for all stage II/III GC patients. Additionally, In addition to the early detection of recurrence, the optimal follow-up strategy should also balance cost and effectiveness. There were no criteria for the arrangement of follow-up in different guidelines, and the optimal postoperative follow-up strategy for patients with stage II/III GC remains unclear.

Methods Prospectively collected data from stage II/III GC patients (n=1,661) who underwent gastrectomy at Fujian Medical University Union Hospital (FJMUUH) between January 2010 and October 2015. For external validation, two independent cohorts were included, which were composed of 380 stage II/III GC patients who underwent gastrectomy at the Mayo Clinic between July 1991 and July 2012 and 270 stage II/III GC patients at the Qinghai university affiliated hospital (QUAH) between May 2010 and Oct 2014. Random survival forest models were used to predict dynamic recurrence hazards and to construct individual surveillance strategies for stage II/III GC. Cost-effectiveness were assessed by Markov model.
BACKGROUND: Ileal pouch anal anastomosis (IPAA) circumferential pouch advancement (CPA) involves full-thickness transanal 180-360° dissection of the distal pouch, allowing the advancement of healthy bowel to cover the internal opening of a vaginal fistula. We aimed to describe the long-term outcomes of this rare procedure.
METHODS: Patients with IPAA who underwent transanal pouch advancement for any indication between 2009 and 2021 were included. Demographics, operative details, and outcomes were reviewed. An early fistula was defined as occurring within 1 year of IPAA construction. Clinical success was defined as resolution of symptoms necessitating CPA, pouch retention, and no stoma at the time of follow-up. Figures represent the median (interquartile range) or frequency (%).
RESULTS: Over a 12-year period, nine patients were identified; the median age at CPA was 41 (36-44) years. Four patients developed early fistula after index IPAA, and five developed late fistulae. The median number of fistula repair procedures prior to CPA was 2 (1-2). All patients were diagnosed with ulcerative colitis at the time of IPAA and all late patients were re-diagnosed with Crohn's disease. Four (44.4%) patients had ileostomies present at the time of surgery, three (33.3%) had one constructed during surgery, and two (22.2%) never had a stoma. The median follow-up time was 11 (6-24) months. Clinical success was achieved in four of the nine (44.4%) patients at the time of the last follow-up.
CONCLUSIONS: Transanal circumferential pouch advancement was an effective treatment for refractory pouch vaginal fistulas and may be offered to patients who have had previous attempts at repair.
CASE: We present a case of a 67-year-old female patient with concomitant cervical spondylotic myelopathy (CSM) and Guillain-Barré syndrome (GBS). Surgical intervention, including cervical decompression and arthrodesis, was performed to address cervical myelopathy symptoms. Despite initial improvement, the patient's motor function deteriorated, leading to the diagnosis of GBS. The patient's hospital course was protracted with a complicated recovery.
CONCLUSION: This case emphasizes the clinical details of coexisting CSM and GBS, highlighting the importance of diagnosing and considering demyelinating diseases when determining the optimal timeline for surgical intervention. These findings inform decision-making for clinicians encountering similar patient presentations.
RCT is completed. However, the eligibility was 18 y/o or greater and living in Greater Boston area. The participants used an evidenced based dietary intervention for 3 months and then were randomized to 1 of 3 arms. Those in the experimental arm received a 6 mo intervention based on social cognitive theory or goal systems theory. The intervention was designed to help the participants maintain previously achieved changes in the their diet, e.g., fruits and vegetables. The outcome measures are fruit and vegetable consumption as measured by servings on multiple dietary measures as well as a 24 hr dietary recall.
BACKGROUND: Weight loss and lifestyle interventions are the mainstay of treatment in pediatric NAFLD. There are gaps in the literature on the objective improvement in BMI to meaningfully impact NAFLD in children.
AIM: To determine the decrease in BMI associated with a significant decline in ALT and other metabolic parameters.
METHODS: Retrospective chart review of pediatric patients with the diagnosis of NAFLD. Data were collected at the baseline and 6 and 12 months. A linear regression model was used to assess the percent change in BMI predictive of change in ALT and other metabolic parameters.
RESULTS: 281 charts were included. 71% of patients who had up to a 2.5% loss in BMI at 6 months had a decrease in ALT of up to 10 U/L compared to 43% patients who did not have a decrease in BMI up to 2.5% loss at the same time period (P=0.01). The linear regression model showed that 6-month and 12-month percent changes in BMI are predictive of 6-month and 12-month ALT changes (P=0.01 and 0.02), respectively. ALT normalization was achieved on 12% of patients with a ≥2.5% decrease in BMI at 6 months compared to 1% of patients that had no decrease of ≥2.5% decrease in BMI at 6 months (P=0.01). The mean BMI Z-score decline was 0.18 (P=0.001) in the group with a ≥2.5% decrease in BMI at 6 months.
CONCLUSIONS: BMI loss of up to 2.5% and the mean BMI Z-score 0.18 are associated with a significant decrease in ALT of up to 10 U/L. BMI percent change at 6 months and 12 months is predictive of changes in ALT. These results should help guide providers in clinical practice set objective goals for the management of children with NAFLD resulting from obesity.
Patients receive oncolytic HSV-1716 IT and peritumorally after undergoing surgical tumor resection. Patients also receive dexamethasone IV prior to and 6 and 12 hours after surgery.
The trial is prospective, randomised, open-label, placebo-controlled. The start date of patient enrolment was January 29 of 2019. Simple randomization was performed to allocate subjects into two groups using the Microsoft Excel random number generator. As a result of randomisation, subjects were allocated into two groups - Group1 and Group2.

In this study, each subject from Group1 received injection of local anaesthetic into the left arm and sterile saline as a placebo into the right arm, the injections were performed with MicronJet600 and followed by the intravenous cannulation; each subject from Group2 will receive injection of local anaesthetic into the left arm, which was performed with MicronJet600 and followed by the intravenous cannulation, with no pre-treatment prior to the intravenous cannulation in case of the right arm. Pain caused by the cannulations was rated by the subjects in accordance with 100-point visual analogue scale. Safety parameters was assessed throughout the study.
BACKGROUND: medial temporal lobe epilepsy (mTLE) is among the most common types of temporal lobe epilepsy (TLE) ,it is generally resistant to drug treatment, which significantly impacts the quality of life and treatment. Research on novel therapeutic approaches for mTLE has become a current focus. Our study aims to construct and analyze a competing endogenous RNA (ceRNA) network that targets neuroinflammation using publicly available data, which may offer a novel therapeutic approach for mTLE.
METHODS: we utilized the R package to analyze GSE186334 downloaded from Gene Expression Omnibus database, subsequently constructing and identifying hub network within the ceRNA network using public databases. Lastly, we validated the expressions and interactions of some nodes within the hub ceRNA network in Sombati cell model.
RESULTS: our transcriptome analysis identified 649 differentially expressed (DE) mRNAs (273 up-regulated, 376 down-regulated) and 36 DE circRNAs (11 up-regulated, 25 down-regulated) among mTLE patients. A total of 23 candidate DE mRNAs associated with neuroinflammation were screened, and two ceRNA networks were constructed. A hub network was further screened which included 3 mRNAs, 22 miRNAs, and 11 circRNAs. Finally, we confirmed the hsa-miR-149-5p is crucial in the regulatory effect of hsa_circ_0005145 on IL - 1α in the hub network.
CONCLUSIONS: In summary, our study identified a hub ceRNA network and validated a potential circRNA-miRNA-mRNA axis targeting neuroinflammation. The results of our research may serve as a potential therapeutic target for mTLE.
Each patient receive a single intravenous injection of 18F-MFBG 2-4 MBq/kg and undergo PET/CT scan after 60 min post-injection. Patients with neuroblastoma should have a routine clinical 123I-MIBG scintigraphy (planar and/or SPECT/CT) performed within 6 months prior to the inclusion visit or scheduled within 3 months after the inclusion visit. According to patients' condition and clinical management, part of patients with PPGL and NB will receive 68Ga-DOTATATE PET/CT, comparing with 18F-MFBG PET/CT.
Stable dose of insulin peglispro (0.2 - 0.8 units per kilogram \[U/kg\]) administered subcutaneously (SC) once daily for at least 21 days in one of two treatment periods. Dose based on prestudy basal insulin dosing regimen.
According to World Health Organization (2017), each year, diarrhea kills 525,000 children under 5 and there are nearly 1.7 billion cases of diarrheal diseases which are due to infection, contaminated drinking water, contaminated food and many more. One of the major causes of diarrhea is the Escherichia coli also known as E. coli which may cause bloody diarrhea, common during summer. Aside from E. Coli, Salmonella is also one of the causes of diarrhea as well as food poisoning. Treating the E.coli as well as Salmonella is quite hard for the reason that antibiotics is unable to eliminate the said bacteria. On the other hand, isothiocyanates a group wherein sulforaphene belongs is effective against Escherichia coli by inhibiting the bacterial growth and lytic development of stxharboringprohages involving the induction of global bacterial stress regulatory system, (Nowicki et al., 2016). Based from the reasons stated the researchers were encouraged to conduct the study regarding the determination of effectiveness of antimicrobial properties of sulforaphene extracted from radish sprouts to Escherichia coli and Salmonella Typhimurium. The radish seeds undergone germination method first for 8 days in order to achieve a semideveloped radish sprouts then after that the Department of Science and Technology extracted glucoraphenin, the precursor to sulforaphene and the natural inducer of phase 2 detoxification enzymes which is the major component of an 8-day old radish sprout. In extracting the glucoraphenin, the fresh radish sprouts, 780.0 g were blended or osteorized and soaked in 2.0 L of 95 pcnt ethyl alcohol for 48 hours. Meanwhile, mechanical extraction was conducted to get the myrosinase. Afterwards, two compounds were converted to Sulforphene (SFE). Testing and validation of the SFE was held in the DOST. The sulforaphene from eight-day old radish sprouts got a triple positive (+++) with a value of 3 and verbal interpretation of complete, reactivity of mile with a value of 2 and a total mean zone of inhibition from the first and second trial of 10 millimeter. For comparison, The sulforaphene in 8-day old radish sprouts got an inhibitory activity of 3 with a verbal interpretation of complete, reactivity of 2 with a verbal interpretation of mild and zone of inhibition total mean of 10 millimeter as compared to the amikacin, which got an inhibitory activity of 3 with a verbal interpretation of complete, reactivity of 3 with a verbal interpretation of moderate and zone of inhibition total mean of 12.81 millimeter in E. Coli and 13. 13. mm in S. Typhimurium. The potentiality of sulforaphene was p-value of 0.73 and 0.69 which was derived from observed value inhibitory activity of three (3), reactivity of two (2), total mean of zone of inhibition of 10 and expected value from amikacin having an inhibitory activity of 3, reactivity of 2 and a total mean of zone of inhibition of 12.81 millimeter and 13.13 millimetre.
The present invention relates to glial cell line-derived neurotrophic factor (GDNF), a potent neurotrophin that exhibits a broad spectrum of biological activities on a variety of cell types from both the central and peripheral nervous systems. The present invention involves the cloning and characterization of a high affinity receptor for GDNF. This molecule has been named GDNF receptor (GDNFR) since it is the first known component of a receptor system. Nucleic acid and amino acid sequences are described for GDNFR protein products. A hydrophobic domain with the features of a signal peptide is found at the amino terminus, while a second hydrophobic domain at the carboxy terminus is involved in the linkage of the receptor to the cell membrane. The lack of a transmembrane domain and cytoplasmic region indicates that GDNFR requires one or more accessory molecules in order to mediate transmembrane signaling. GDNFR mRNA is widely distributed in both nervous system and non-neural tissues, consistent with the similar distribution found for GDNF.
The routine use of prophylactic drainage has become common in many hospitals around the world after cholecystectomy for different reasons. In elective surgeries, the evidence does not support the use of drainage. But in emergency laparoscopic cholecystectomy surgeries, using drainage remains controversial. Surgeons who support the use of drainage find it useful to identify the early complications of surgery and removing intra-abdominal collections, while opponents of drainage use believe that it increases the risk of wound infection. But, a systematic review and meta-analysis discussed the ineffectiveness of the routine use of the prophylactic drainage after laparoscopic cholecystectomy for acute cholecystitis and requested more randomized clinical trial studies on the subject. However, this study and others in the medical literature contain very few high-quality randomized controlled trials, hence our randomized controlled trial compares the use and non-use of drainage in patients undergoing laparoscopic cholecystectomy for different reasons.
Mindfulness skills will take over a 6-week period. Mindfulness skills will deliver in a weekly group format. Participants will be instructed to follow mindfulness practice at home. The program is focused on cultivating mindfulness of present-moment, cultivating a nonreactive, nonjudgmental attitude toward the experience, and includes specific formal and informal practices aimed at cultivating healthy habits and lifestyle (e.g., activities of daily living such as feeding, bathing, or showering and other occupations such as communication management, health management, etc.; and prosocial components (e.g., kindness and compassion).